Загрузка...
Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors
BACKGROUND: BCR-ABL kinase domain (KD) mutations are detected in approximately 45% of imatinib-resistant CML. Patterns of KD mutations in Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) are less well-studied. METHODS: We assessed KD mutations in relapsed Ph+ ALL following treatments...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204653/ https://ncbi.nlm.nih.gov/pubmed/18615627 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23666 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|